These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22213159)

  • 1. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
    Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
    Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
    Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
    Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
    Huang W; Fridman Y; Bonfil RD; Ustach CV; Conley-LaComb MK; Wiesner C; Saliganan A; Cher ML; Kim HR
    Oncogene; 2012 Oct; 31(42):4527-35. PubMed ID: 22158043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
    Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
    Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
    Kong D; Banerjee S; Huang W; Li Y; Wang Z; Kim HR; Sarkar FH
    Cancer Res; 2008 Mar; 68(6):1927-34. PubMed ID: 18339874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.
    Chen Y; Gera L; Zhang S; Li X; Yang Y; Mamouni K; Wu AY; Liu H; Kucuk O; Wu D
    Cancer Lett; 2019 Apr; 446():62-72. PubMed ID: 30660650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
    Momeny M; Sankanian G; Hamzehlou S; Yousefi H; Esmaeili F; Alishahi Z; Karimi B; Zandi Z; Shamsaiegahkani S; Sabourinejad Z; Kashani B; Nasrollahzadeh A; Mousavipak SH; Mousavi SA; Ghaffari SH
    Eur J Pharmacol; 2020 Sep; 882():173298. PubMed ID: 32593665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
    Xu L; Tong R; Cochran DM; Jain RK
    Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
    Yin JJ; Zhang L; Munasinghe J; Linnoila RI; Kelly K
    Cancer Res; 2010 Nov; 70(21):8662-73. PubMed ID: 20959486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
    Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
    Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDGF-D signaling: a novel target in cancer therapy.
    Wang Z; Kong D; Li Y; Sarkar FH
    Curr Drug Targets; 2009 Jan; 10(1):38-41. PubMed ID: 19149534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
    Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
    Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
    Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
    Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.